Browse News

Found 66,950 articles

• 

  Mathai Mammen Finds New Home at FogPharma

  3/31/2023

  Nearly eight months after leaving his post as head of R&D at Johnson & Johnson, Mathai Mammen has found a new job as CEO of cancer focused FogPharma.

• Influenza A Virus and the Test Way

  3/31/2023

  Influenza ( short for influenza) is a common acute respiratory infectious disease caused by influenza virus, common in winter and spring. It is also a highly contagious and rapidly spreading disease. It is mainly transmitted through airborne droplets, person-to-person contact or contact with contaminated objects.

• TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

  3/31/2023

  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of BRIUMVI™ (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

• Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

  3/31/2023

  Cabaletta Bio, Inc. (Nasdaq: CABA) today announced that the Company’s Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been cleared by the U.S. Food and Drug Administration (FDA).

• NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

  3/31/2023

  NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced its financial results for the full year ended December 31, 2022 and provided a corporate update.

• Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

  3/31/2023

  Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that adult patient enrollment is complete as of today in its pivotal ASPEN study of brensocatib. 

• Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

  3/31/2023

  Fennec Pharmaceuticals Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion and recommended granting a Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) – known as PEDMARK® in the U.S. – for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localized, non-metastatic, solid tumors.

• Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

  3/31/2023

  Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2022, and recent corporate highlights.

• I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

  3/31/2023

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.

• Genscript Biotech Reports 2022 Annual Results*

  3/31/2023

  GenScript Biotech, the world's leading biotech company, announces its annual results as of December 31, 2022.

• CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022

  3/31/2023

  CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced financial results for the twelve months ended 2022 and corporate update.

• HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

  3/31/2023

  HUTCHMED Limited announces that it completed the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1, -2 and -3, for the treatment of refractory metastatic colorectal cancer.

• Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022

  3/31/2023

  Everest Medicines announced its financial results for the full year ended December 31, 2022, along with a corporate update.

• Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

  3/31/2023

  Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.

• Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/31/2023

  Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its fourth quarter and full-year 2022 financial results and provided a corporate update.

• Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

  3/31/2023

  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022.

• Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

  3/31/2023

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2022.

• Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress

  3/31/2023

  Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 – 6 in Washington D.C.

• Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium

  3/31/2023

  Jasper Therapeutics, Inc. (NASDAQ: JSPR) today announced that it will participate at the Cantor Fitzgerald The Future of Oncology Virtual Symposium, to be held from April 3-5, 2023 in a virtual format.

• Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

  3/31/2023

  Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid") announced that, yesterday, the MolDX Program ("MolDX") published a Future Effective Local Coverage Determination ("LCD") L39256, on molecular testing for esophageal precancer and cancer in Medicare beneficiaries, to become effective May 14, 2023.